Alnylam Pharmaceuticals, Inc.
ALNY
Kedudukan dalam Saham
#787
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily... Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Harga Saham
$230.76
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$30.88B
Perubahan (1 hari)
-1.08%
Perubahan (1 tahun)
-51.32%
Negara
US
Perdagangan Alnylam Pharmaceuticals, Inc. (ALNY)
Kategori
Healthcare
Nisbah P/E bagi Alnylam Pharmaceuticals, Inc. (ALNY)
Nisbah P/E pada October 2026 TTM: 36.80
Menurut laporan kewangan dan harga saham terkini Alnylam Pharmaceuticals, Inc., nisbah P/E semasa (TTM) ialah 36.80. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -54.31.
Sejarah nisbah P/E bagi Alnylam Pharmaceuticals, Inc. dari 2002 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 36.80 | -134.08% |
| 2024 | -107.99 | 98.85% |
| 2023 | -54.31 | 112.42% |
| 2022 | -25.57 | 8.55% |
| 2021 | -23.55 | 35.27% |
| 2020 | -17.41 | 22.61% |
| 2019 | -14.20 | 47.45% |
| 2018 | -9.63 | -58.91% |
| 2017 | -23.44 | 199.93% |
| 2016 | -7.81 | -71.33% |
| 2015 | -27.26 | 36.35% |
| 2014 | -19.99 | -54.93% |
| 2013 | -44.36 | 412.40% |
| 2012 | -8.66 | 44.38% |
| 2011 | -6.00 | -37.06% |
| 2010 | -9.53 | -38.20% |
| 2009 | -15.41 | -60.17% |
| 2008 | -38.70 | 194.23% |
| 2007 | -13.15 | -33.30% |
| 2006 | -19.72 | 188.58% |
| 2005 | -6.83 | 151.30% |
| 2004 | -2.72 | 1,101.55% |
| 2003 | -0.23 | -53.00% |
| 2002 | -0.48 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -21.79% |
US
|
|
| -28.36 | -177.06% |
US
|
|
| -24.57 | -166.76% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -17.58% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.